# Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis

> **NCT02507570** · PHASE2 · COMPLETED · sponsor: **Carolina Research Professionals, LLC** · enrollment: 40 (actual)

## Conditions studied

- Prostate Carcinoma Metastatic to the Bone

## Interventions

- **DRUG:** Enzalutamide
- **RADIATION:** Radium ra 223 dichloride

## Key facts

- **NCT ID:** NCT02507570
- **Lead sponsor:** Carolina Research Professionals, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-23
- **Primary completion:** 2019-01-18
- **Final completion:** 2019-01-18
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2019-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02507570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02507570, "Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02507570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*